Literature DB >> 29793647

Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?

Umang Swami1, Petar Lenert2, Muhammad Furqan1, Taher Abu Hejleh3, Gerald Clamon1, Jun Zhang4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29793647     DOI： 10.1016/j.jtho.2018.01.027

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

Review 1.  Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.

Authors:  Francesco Facchinetti; Paola Bordi; Alessandro Leonetti; Sebastiano Buti; Marcello Tiseo
Journal:  Drug Des Devel Ther       Date:  2018-09-10       Impact factor: 4.162

2.  Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.

Authors:  Noha Abdel-Wahab; Maria E Suarez-Almazor
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

Review 3.  The dark side of immunotherapy.

Authors:  Nwanneka Okwundu; Douglas Grossman; Siwen Hu-Lieskovan; Kenneth F Grossmann; Umang Swami
Journal:  Ann Transl Med       Date:  2021-06

4.  Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer.

Authors:  Navdeep Singh; Nagashree Seetharamu
Journal:  BMJ Case Rep       Date:  2020-08-24

5.  Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.

Authors:  Gang Liu; Wenxuan Zhou; Xiaoli Li; Lijie Guo; Tingting He; Juan Zhao; Liansheng Gong
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.